MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jjcc.2015.07.017

Медицинская библиотека · Journal of cardiology · 2015

Randomized controlled trial of TY-51924, a novel hydrophilic NHE inhibitor, in acute myocardial infarction.

Kimura Kazuo, Nakao Koichi, Shibata Yoshisato, Sone Takahito, Takayama Tadateru, Fukuzawa Shigeru, Nakama Yasuharu, Hirayama Haruo, Matsumoto Naoya, Kosuge Masami, Hiro Takafumi, Sakuma Hajime, Ishihara Masaharu, Asakura Masanori, Hamada Chikuma, Kaneko Akira, Yokoi Toshiaki, Hirayama Atsushi, AMITY study group

Клиническое исследование II фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

In patients with ST-elevation acute myocardial infarction (STEMI), reperfusion therapy limits infarct size, but can directly evoke myocardial reperfusion injury. Activation of the Na(+)/H(+) exchanger (NHE) plays an important role in reperfusion injury. TY-51924, a novel NHE inhibitor, significantly reduced infarct size in animal studies and was well tolerated in early-phase clinical trials. This study aim was to evaluate the efficacy and safety of TY-51924 in patients with STEMI.

METHODS

In this multicenter, randomized, double-blind, placebo-controlled Phase II trial, 105 patients with first anterior STEMI undergoing primary percutaneous coronary intervention (pPCI) were randomly assigned to receive an intravenous infusion of either TY-51924 or placebo. Primary endpoints were myocardial salvage index (MSI) as determined by single photon emission computed tomography (SPECT) 3-5 days after pPCI and safety up to 7 days.

RESULTS

Baseline characteristics were similar in the two groups. MSI 3-5 days after pPCI (0.200 vs. 0.290, p=0.56), 3 months after pPCI (0.470 vs. 0.500, p=0.76), and the incidences of side effects did not differ between the two groups as a whole. However, on post hoc analysis of 52 patients with a large area at risk (AAR) (≥38%) and no antegrade coronary flow, MSI by SPECT at 3 months after pPCI was significantly higher in TY-51924 group (0.450 vs. 0.320, p=0.03). TY-51924 did not adversely influence hemodynamics.

CONCLUSIONS

TY-51924 did not improve MSI or increase side effects as a whole. However, TY-51924 is potentially cardioprotective in the presence of a large AAR and no antegrade coronary flow.

Для цитирования: Kimura Kazuo, Nakao Koichi, Shibata Yoshisato, Sone Takahito, Takayama Tadateru, Fukuzawa Shigeru, Nakama Yasuharu, Hirayama Haruo, Matsumoto Naoya, Kosuge Masami, Hiro Takafumi, Sakuma Hajime, Ishihara Masaharu, Asakura Masanori, Hamada Chikuma, Kaneko Akira, Yokoi Toshiaki, Hirayama Atsushi, AMITY study group. Randomized controlled trial of TY-51924, a novel hydrophilic NHE inhibitor, in acute myocardial infarction.. Journal of cardiology. 2015. DOI: 10.1016/j.jjcc.2015.07.017.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.